Inhalopédia | Inhalers

Class
- Long-acting muscarinic antagonist (LAMA)
  Long-acting beta-2 agonist (LABA)
Active ingredient
- Glycopyrronium (as bromide)
- Indacaterol (as maleate)
Device
- Breezhaler®
Inhalers techniques and maintenance
Age
- 18 +
Typical use
- Asthma (off-label)
  in addition to an ICS, when uncontrolled on high dose ICS + LABA
Asthma management principles
- COPD
  uncontrolled on 1 bronchodilator (LAMA or LABA)
COPD management principles
Marketed strength
- 50/110 mcg
Number of doses
- 30 doses
Dose indicator
- Yes | Number of capsules
Usual adult dosage
- 1 inh QD
Usual pediatric dosage
- -
Required inspiratory flow
- > 50 L/min
  Low internal resistance (R1)
Inspiratory flows
Public coverage
- MN – NIHB | Open/Regular Benefit
  All provinces except MN – NIHB | Restricted Benefit with criteria
Provincial coverage criteria
Advantages
- Low internal resistance (less effort required for inhalation)
- Clear capsule which ensures complete inhalation
Disadvantages
- Capsule handling required
- The capsule may get stuck while rotating during inhalation
- Cough when inhaling too quickly
- Capsule may be ingested
Side effects

Product monograph

Download

Ultibro®